Vaccines

Pricing and Reimbursement (P&R) Strategy

Create a P&R strategy that meets your business goals

P&R strategies that deliver commercial success

Alira Health provides a range of P&R strategies and solutions that deliver commercial success, including:
  • A comprehensive, structured overview of your target market characteristics (e.g., public, private, travel, occupational health, including epidemiological situation)
  • Recommendations for different pricing scenarios for different patient groups
  • Analysis and recommendations for reference prices strategies for vaccines
  • Development of a pricing simulator and assessment of pricing influences across your target market
  • Creation of a commercialization strategy in different market segments
  • KOL analysis and KOL feedback collection to support reimbursement negotiations

Why choose Alira Health?

When you partner with us, you’ll benefit from:

  • Access to a multidisciplinary team of vaccine experts, economists, regulatory experts, and strategic consultants
  • A strategic approach to P&R strategy development with a focus on long-term impact
  • Access to a full continuum of services, such as patient engagement, regulatory, and much more
  • Extensive global network of external experts

Working together to transform healthcare

Whether you need to understand which asset best aligns with your long-term strategy, which new market or therapeutic area to explore, or how to expand into another sector, we are ready to help you lead the way.

Contact us
Bernd Schollmeier
Bernd Shollmier
Vice President of Global Market Access Vaccines
We are seeing a lot of traction in the industry, as well as interest in vaccine production. To support companies in a challenging payer environment, we created a dedicated vaccine division in our Global Market Access department to provide a variety of solutions that maximize patient access and the gross-to-net value of the product across the full product lifecycle.

Related News

Publications May 27, 2022
The Impact of Chip Shortage on the MedTech Sector and RAS Players
Discover the three factors driving the chip shortage, the impact, and what’s next for Robotic and MedTech industry at large.
CDMO MedTech Robotcs
News May 11, 2022
Alira Health Acquires RedCrow, an Equity Crowdfunding Platform for Healthcare Startups
We acquired RedCrow, an alternative investment platform that provides individual investors with easy access to expert-vetted healthcare start-ups. The financial terms of the transaction(...)
MedTech Patient Engagement Pharma
Multimedia May 10, 2022
VacciTalks: Behind the Scenes: Challenging Race of Vaccine Development
Join the 2nd episode of VacciTalks where together with vaccine expert Roberto Camerini we will peek behind the scenes of vaccine development and get an insider look at the difficulties,(...)
Market Access
Events May 9, 2022
7e Journée start-up innovantes du dispositif médical
Clinical Digital Health Market Access MedTech Research & Development
Multimedia April 28, 2022
Alira Health’s Transformation Talks: Real-World Data to Support HTAs in Europe
Learn more about RWD as a support in HTAs and its direct impact on HTAs budgets, results, and even patient outcomes by listening to this episode of Transformation Talks.
Clinical Market Access RWE
Publications April 20, 2022
White Paper: Next Generation Therapies: Access, Pricing and Ethical Issues in Perspective
In this white paper, we will explore wide range of new therapies we term “Next Generation Therapies” and challenges related to them.
Market Access
Publications April 8, 2022
Cheat Sheet: MDCG Guidance on Medical Device Classification
Assigning the proper class to a medical device (MD) is one of the most important activities carried out by a manufacturer. Read Alira Health's cheat sheet MDCG Guidance on Medical Device(...)
MedTech Regulatory
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.